Chargement en cours...

CTLA-4 blockade: therapeutic potential in cancer treatments

Enhancing or prolonging T-cell activation by monoclonal antibodies (mAbs) blocking negative signaling receptors such as CTLA4 is one approach to overcoming tumor-induced immune tolerance. Ipilimumab and tremelimumab inhibit CTLA4, prolonging antitumor immune responses and leading to durable anti-tum...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tarhini, Ahmad A, Iqbal, Fatima
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2010
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2895779/
https://ncbi.nlm.nih.gov/pubmed/20616954
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!